Search the Newsreel

Leerink Partners Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $110

Leerink Partners has reiterated its Buy rating on Twist Bioscience (TWST.US) and increased its price target to $110. This signals continued confidence from the firm in the biotechnology company's future performance and growth prospects.

Why is Piper Sandler Bullish on Twist Bioscience (TWST)

Piper Sandler initiated coverage on Twist Bioscience (TWST) with an Overweight rating and an $85.00 price target, citing confidence in its synthetic biology platform and potential for significant upside despite current overvaluation according to GuruFocus. The company is strategically focused on achieving adjusted EBITDA …

Twist Bioscience plans 8 a.m. ET call for fiscal Q3 update

Twist Bioscience will report its fiscal 2026 third-quarter financial results before market open on Monday, August 3, 2026. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the results and provide …

Press Release: Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026

Twist Bioscience is scheduled to report its fiscal 2026 third-quarter financial results on Monday, August 3, 2026. Separately, Unity Software reported strong fourth-quarter financial results with revenue increasing 35% year-over-year to $609 million, exceeding analyst estimates, despite reporting a quarterly loss of 66 cents …

Twist Bioscience (TWST) Stock Could Be 25.5% Overvalued After Its Recent Rally

Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?

Earnings call transcript: Twist Bioscience Q2 2026 EPS miss, stock rises

Twist Bioscience Corporation Q2 2026 Earnings Call Summary

Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates

TD Cowen raises Twist Bioscience stock price target on revenue beat

Twist Bioscience Expands Antibody Discovery With Invenra Bispecific Platform Deal

Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 30%

Twist Bioscience (TWST) Is Down 11.2% After Record Revenue and MRD Express Launch Plans Announced